A method for preparing biosynthetic human structural material
By designing the amino acid sequence of recombinant type III collagen and using TEV protease removal technology, the problems of in vitro expression and immunogenicity are solved, and efficient and low-cost collagen preparation is achieved, which is suitable for the pharmaceutical field.
Patent Information
- Application Number
- CN202410282175.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2023-03-24
- Filing Date
- 2023-07-14
- Publication Date
- 2024-11-15
- Estimated Expiration
- 2043-07-14
AI Technical Summary
The prior art is difficult to correctly express and prepare human type III collagen in vitro, and traditional methods have risks of immunogenicity and viral contamination, which limits its application in the pharmaceutical field.
By designing the amino acid sequence of recombinant type III collagen, including multiple repeat sequences, and using TEV protease to remove amino acid sequences and vectors, efficient expression and purification in E. coli, reducing the immune response risk.
Recombinant type III collagen was successfully correctly expressed and prepared in vitro in large quantities, which has low immunogenicity, simplified the production process, achieved high yield, and was suitable for the fields of medicine and cosmetics.
Smart Images

Figure CN118047857B_ABST
Abstract
Description
[0001] This application is a divisional application of Chinese patent application 202310869570.3. The application date of the original application 202310869570.3 is July 14, 2023, and its name is “A method for preparing biosynthetic human structural materials”.
[0002] Priority and related applications
[0003] The present invention claims priority to Chinese patent application No. 202310298415.0 filed on March 24, 2023, entitled “A method for preparing a biosynthetic human structural material”, and all the contents of this application including the appendix are incorporated herein by reference. Technical Field
[0004] The invention relates to the field of biotechnology, and in particular to a method for preparing a biosynthetic human body structural material. Background Art
[0005] The structural materials of the human body are mainly structural proteins including collagen. This type of protein has adhesion and supporting functions for cells and tissues and is the main component of the extracellular matrix.
[0006] Collagen is a type of protein widely distributed in human connective tissues. It is also the most abundant protein in the human body, accounting for 25% to 35% of the total protein. Its main functions are to maintain the extracellular environment, maintain the normal physiological functions of tissues and organs, and repair body damage. Collagen is a natural biological resource with good bio-tissue compatibility that other polymer materials cannot match, as well as excellent support elasticity and degradability for cells. Therefore, collagen can be widely used in industries such as medicine and cosmetics.
[0007] Natural collagen molecules can form a special superhelical structure, which is a left-handed helix with three amino acid residues as the basic repeating body. These three amino acid residues are usually Gly-X-Pro. Among them, Gly represents glycine, X represents any natural amino acid, and Pro represents proline. Gly is necessary for the formation of hydrogen bonds in collagen. It has no side chains and can therefore make collagen densely packed and maintain skin tension and elasticity. As people age, the collagen in the dermis degrades and ages, and the skin becomes dry and wrinkles appear. In order to prevent skin aging, some scholars have studied the process of delaying skin aging by supplementing collagen.
[0008] The traditional method of producing collagen is to use acid, alkali, and enzymatic hydrolysis to treat animal-derived tissues and extract collagen derivatives. The collagen prepared by the traditional method of producing collagen does not have the corresponding biological activity, and there are immunogenicity caused by different species and multiple viral contaminations carried by living animals themselves, which has a greater safety risk. With the development of modern technology, recombinant collagen can be produced by genetic engineering technology. The recombinant collagen prepared by this method has low immunogenicity and good biological activity, and can be widely used in various fields of biomedicine. However, how to select an amino acid sequence that has function and can be expressed in large quantities for large-scale production from the human collagen sequence is the difficulty we are facing at present. Therefore, a biosynthetic method of recombinant type III collagen that can overcome this defect is urgently needed so that it can be widely used as a structural material for the human body. Summary of the invention
[0009] Problem that the invention aims to solve
[0010] The present invention provides a recombinant type III collagen, and provides a biosynthetic preparation method thereof, and its use in the medical field, so as to solve the problem that natural human type III collagen cannot be correctly expressed and prepared in large quantities in vitro, and provide new possibilities for the production and application of humanized collagen.
[0011] Solutions for solving problems
[0012] In a first aspect, the present invention provides a recombinant type III collagen, characterized in that the amino acid sequence of the recombinant type III collagen comprises n repeating sequences, where n is an integer greater than or equal to 1; wherein the repeating sequence is a functional region sequence of human natural type III collagen;
[0013] In some preferred embodiments, n is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or 16, wherein when n is an integer greater than or equal to 2, each repeated sequence is directly connected;
[0014] In some more preferred embodiments, said is 4, 8 or 16;
[0015] In some most preferred embodiments, the amino acid sequence of the recombinant type III collagen comprises any one of the following (i) to (iii):
[0016] (i) an amino acid sequence as shown in SEQ ID NO.1, SEQ ID NO.3, SEQ ID NO.5, SEQ ID NO.7, SEQ ID NO.9, SEQ ID NO.11, SEQ ID NO.13, SEQ ID NO.15, SEQ ID NO.17, SEQ ID NO.19 or SEQ ID NO.21;
[0017] (ii) an amino acid sequence in which one or more amino acid residues are added, substituted, deleted or modified in the amino acid sequence as shown in SEQ ID NO.1, SEQ ID NO.3, SEQ ID NO.5, SEQ ID NO.7, SEQ ID NO.9, SEQ ID NO.11, SEQ ID NO.13, SEQ ID NO.15, SEQ ID NO.17, SEQ ID NO.19 or SEQ ID NO.21 and the cell adhesion effect of human natural type III collagen is retained;
[0018] (iii) an amino acid sequence encoded by a nucleotide sequence, wherein the nucleotide sequence hybridizes with a polynucleotide sequence encoding a sequence as shown in SEQ ID NO.1, SEQ ID NO.3, SEQ ID NO.5, SEQ ID NO.7, SEQ ID NO.9, SEQ ID NO.11, SEQ ID NO.13, SEQ ID NO.15, SEQ ID NO.17SEQ ID NO.19 or SEQ ID NO.21 under stringent conditions, and the amino acid sequence retains the cell adhesion effect of human natural type III collagen, and the stringent conditions are medium stringent conditions, medium-high stringent conditions, high stringent conditions or very high stringent conditions.
[0019] In some specific embodiments, the amino acid sequence of the recombinant type III collagen described in the first aspect of the present invention comprises an amino acid sequence that can be removed by TEV protease, and the amino acid sequence that can be removed by TEV protease is shown in SEQ ID NO.23;
[0020] In some preferred embodiments, the amino acid sequence capable of being removed by TEV protease is directly linked to the repetitive sequence;
[0021] In some more preferred embodiments, the amino acid sequence capable of being cleaved by TEV protease is located at the N-terminus of the recombinant type III collagen.
[0022] In a second aspect, the present invention provides a polynucleotide encoding the recombinant type III collagen described in the first aspect of the present invention;
[0023] In some preferred embodiments, the sequence of the polynucleotide comprises a sequence as shown in SEQ ID NO.2, SEQ ID NO.4, SEQ ID NO.6, SEQ ID NO.8, SEQ ID NO.10, SEQ ID NO.12, SEQ ID NO.14, SEQ ID NO.16, SEQ ID NO.18, SEQ ID NO.20 or SEQ ID NO.22.
[0024] The present invention provides a recombinant expression vector in a third aspect, characterized in that the recombinant expression vector comprises the polynucleotide as described in the second aspect of the present invention;
[0025] In some preferred embodiments, the recombinant expression vector includes a pET series vector, a shuttle vector, a phage or a viral vector;
[0026] In some more preferred embodiments, the recombinant expression vector is pET-32a.
[0027] The present invention provides a recombinant host cell in a fourth aspect, characterized in that the recombinant host cell comprises the recombinant expression vector described in the third aspect of the present invention;
[0028] In some preferred embodiments, the recombinant host cell is a prokaryotic cell, a yeast or a eukaryotic cell;
[0029] In some more preferred embodiments, the recombinant host cell is Escherichia coli BL21 (DE3).
[0030] The present invention provides in a fifth aspect a method for preparing the recombinant type III collagen described in the first aspect of the present invention, comprising the following steps:
[0031] S1: fermenting and culturing the recombinant host cell according to the fourth aspect of the present invention to induce protein expression;
[0032] S2: collecting the protein;
[0033] S3: Purify the protein; in some preferred embodiments, it comprises purifying the protein using a Ni affinity chromatography column and / or an ion exchange chromatography column.
[0034] In some specific embodiments, in the S1 step, the fermentation culture is carried out in a shaking incubator at a rotation speed of 200-240 rpm and a temperature of 35-38°C; in some preferred embodiments, the fermentation culture is carried out in a shaking incubator at a rotation speed of 220 rpm and a temperature of 37°C.
[0035] In some other specific embodiments, in the S1 step, the specific operation of inducing protein expression is: adding IPTG to the amplified cultured bacterial solution and cooling it to 16°C; in some preferred embodiments, the final concentration of IPTG is 0.3-0.7 mM; in some more preferred embodiments, the final concentration of IPTG is 0.5 mM.
[0036] In some specific embodiments, in the S2 step, the specific operation of collecting the protein is: resuspending the bacteria obtained in the S1 step with a balanced working solution containing 20-30mM Tris, 150-250mM sodium chloride and 15-25mM imidazole, cooling the bacterial solution to 4-15°C, and centrifuging at 15000-18000 rpm for 20-40 min at 4°C after high-pressure homogenization.
[0037] In a sixth aspect, the present invention provides use of the recombinant humanized type III collagen described in the first aspect of the present invention in preparing a product, wherein the product includes a medical device, a cosmetic or a medicine.
[0038] Effects of the Invention
[0039] The present invention provides a variety of recombinant type III collagens containing amino acid sequences of human type III collagen functional regions and preparation methods thereof, and tests the protein expression amount and yield of the recombinant type III collagens.
[0040] Through the implementation of the above technical solutions, the present invention provides an amino acid sequence of recombinant type III collagen that can be correctly expressed in vitro, and successfully biosynthesized in vitro. The amino acid sequence of the protein is derived from natural human type III collagen, and will not produce adverse immune reactions when used in the human body. At the same time, the preparation method of the recombinant type III collagen provided by the present invention is simple, and a high yield of recombinant type III collagen can be obtained at a low cost. BRIEF DESCRIPTION OF THE DRAWINGS
[0041] Figure 1 This is the electrophoresis result of recombinant type III collagen. DETAILED DESCRIPTION
[0042] Embodiments of the present invention will be described below, but the present invention is not limited thereto.
[0043] In the present invention, the word "may" includes both performing a certain process and not performing a certain process.
[0044] In the present invention, "optional" or "optionally" means that the subsequently described event or circumstance may or may not occur, and the description includes instances where the event occurs and instances where it does not occur.
[0045] In the present invention, the terms "comprising", "having", "including" or "containing" may mean inclusive or open-ended, and do not exclude additional, uncited elements or method steps. At the same time, "comprising", "having", "including" or "containing" may also mean closed, excluding additional, uncited elements or method steps.
[0046] In the present invention, numerical ranges expressed using “numerical value A to numerical value B,” “numerical value A or higher,” and “numerical value A or lower” mean ranges including the numerical value A and numerical value B at the endpoints.
[0047] In the present invention, any numerical value includes the standard deviation of the error of the device or method used to determine the value. The numerical range and parameters used to define the present invention are all approximate values, and the relevant numerical values in the specific embodiments have been presented as accurately as possible. However, any numerical value inherently inevitably contains the standard deviation caused by the aforementioned testing device or method.
[0048] In the present invention, the terms "polypeptide", "protein" interchangeably refer to a string of at least two amino acid residues linked to each other by covalent bonds (e.g., peptide bonds), which may be recombinant polypeptides, natural polypeptides, or synthetic polypeptides. A polypeptide may be linear or branched, it may contain modified amino acids, and it may be interrupted by non-amino acids. The term also includes amino acid polymers that have been modified (e.g., disulfide bond formation, glycosylation, lipidation, acetylation, phosphorylation, or any other manipulation, such as conjugation with a labeling component).
[0049] In the present invention, the term "amino acid" may include natural amino acids, unnatural amino acids, amino acid analogs, and all their D and L stereoisomers.
[0050] In the present invention, amino acid deletion may refer to deleting 1, 2 or 3 or more amino acids from an amino acid sequence, as long as the altered sequence fully or partially retains the activity of the original amino acid sequence.
[0051] In the present invention, amino acid addition may refer to adding 1, 2 or 3 or more amino acids at the C-terminus, N-terminus or any position between the C-terminus and the N-terminus of the amino acid sequence, as long as the altered sequence fully or partially retains the activity of the original amino acid sequence.
[0052] In the present invention, amino acid substitution may refer to the replacement of an amino acid at a certain position of an amino acid sequence by another amino acid, as long as the altered sequence retains the activity of the original amino acid sequence in whole or in part. Amino acid substitution may be a conservative amino acid substitution, which means that compared with the original amino acid sequence, several amino acids are replaced by amino acids with similar or similar properties to form a peptide (conservative variant peptide). Exemplarily, these conservative variant peptides can be produced according to the following amino acid substitutions: substitution of Ala by Val, Leu or Ile, substitution of Arg by Lys, Gln, Asn or His, substitution of Asn by Gln, His, Lys or Arg, substitution of Asn by Glu or Asn, substitution of Cys by Ser or Ala, substitution of Gln by Asn or Glu, substitution of Glu by Asp or Gln, substitution of Gly by Ala, substitution of His by Asn, Lys, Gln or Arg, substitution of Leu, Met, Ala, Val or P The amino acid substitutions may also be non-conservative amino acid substitutions.
[0053] In the present invention, amino acid modification may include modification of the natural sequence, such as modification of functional groups, intramolecular covalent bonding (e.g., cyclization between side chains), methylation, acylation, ubiquitination, phosphorylation, aminohexanylation, biotinylation, etc.
[0054] In the present invention, "hybridization" means the ability of a polynucleotide or oligonucleotide to bind to a substantially complementary sequence under stringent conditions without non-specific binding to non-complementary objects under these conditions. For this purpose, the sequences are preferably 90-100% complementary. The property of complementary sequences that can specifically bind to each other is applied, for example, in Northern or Southern blotting techniques, or in primer binding for PCR or RT-PCR. According to the present invention, hybridization occurs under moderate stringency conditions, medium-high stringency conditions, high stringency conditions or very high stringency conditions. Such hybridization conditions are described in Current Protocols in Molecular Biology, John Wiley & Sons, NY (1989), 6.3.1-6.3.6. For example, specific hybridization conditions are as follows: (1) low stringency hybridization conditions are in 6× sodium chloride / sodium citrate (SSC) at about 45°C, followed by two washes in 0.2×SSC, 0.1% SDS at at least 50°C (for low stringency conditions, the washing temperature can be increased to 55°C); (2) moderate stringency hybridization conditions are in 6×SSC at about 45°C, followed by one or more washes in 0.2×SSC, 0.1% SDS at 60°C; (3) high stringency hybridization conditions are in 6×SSC at about 45°C, followed by one or more washes in 0.2×SSC, 0.1% SDS at 65°C and preferably; (4) very high stringency hybridization conditions are 0.5 M sodium phosphate, 7% SDS at 65°C, followed by one or more washes in 0.2×SSC, 1% SDS at 65°C.
[0055] In the present invention, suitable vectors are known in the field of vector construction, including the selection of promoters and other regulatory elements, such as enhancer elements. The vectors described in the present invention include sequences suitable for introduction into cells. For example, the vector can be an expression vector in which the coding sequence of the protein is controlled by its own cis-acting regulatory elements, and the design of the vector facilitates gene integration or gene replacement of host cells, etc. It should be understood by those of ordinary skill in the art that in the present invention, "vector" includes DNA molecules, such as plasmids, phages, viruses or other vectors, which contain one or more heterologous or recombinant nucleotide sequences. Suitable phage and viral vectors include, but are not limited to: λ-phage, EMBL phage, simian virus, bovine wart virus, Epstein-Barr virus, adenovirus, herpes virus, mouse sarcoma virus, murine mammary cancer virus, lentivirus, etc.
[0056] In the present invention, the host cell may be a eukaryotic cell, such as fungi and yeast, or a prokaryotic cell, such as Enterobacteriaceae.
[0057] In the present invention, the "functional region of human natural type III collagen" refers to a sequence fragment in human natural type III collagen that has functions such as cell adhesion activity possessed by the collagen amino acid sequence.
[0058] In some preferred embodiments, the sequence of the functional region of human native type III collagen is selected from any one of the following sequences:
[0059] (i)GGKGEMGPAGIPGAPGLMGARGPPGPAGAN (SEQ ID NO: 24)
[0060] (ii)GERGETGPPGPAGFPGAPGQNGEPGGKGER (SEQ ID NO: 25)
[0061] (iii) GetgapglkgenglpgengapgpmgpRgap (SEQ ID NO: 26)
[0062] (iv) Gqpgppgppgtagfpgspgakgevgpagsp (SEQ ID NO: 27)
[0063] (v)GqpgdkgeggapglpgiagpRgspGERget (SEQ ID NO: 28)
[0064] (vi)gqngepggkGERgapGEKgeggppgvagppggs (SEQ ID NO: 29)
[0065] (vii) GpRgpvgpsgppgkdgtsghpgpigppgpRgnRGER (SEQ ID NO: 30) The application fields of the recombinant type III collagen provided by the present invention include the preparation of high-end medical devices, such as biological dressings, human bionic materials, plastic surgery materials, organoid culture, cardiovascular stents, coatings, tissue injection filling, ophthalmic materials, obstetrics and gynecology biomaterials, nerve repair and regeneration, liver tissue and blood vessel repair and regeneration, 3D printing artificial organ biomaterials, etc.; as well as high-end cosmetic raw materials and high-end pharmaceutical excipients, etc.
[0066] Example
[0067] The present invention is further illustrated by the following examples, but any example or combination thereof should not be construed as limiting the scope or implementation of the present invention. The scope of the present invention is defined by the appended claims. In combination with this specification and common knowledge in the art, a person of ordinary skill in the art can clearly understand the scope defined by the claims. Without departing from the spirit and scope of the present invention, a person of ordinary skill in the art can make any modification or change to the technical solution of the present invention, and such modification and change are also included in the scope of the present invention.
[0068] In the examples, if the specific conditions are not specified, the conditions are carried out according to normal conditions or the conditions recommended by the manufacturer. If the manufacturer is not specified for all reagents or instruments, they are all conventional products that can be purchased commercially. In order to better illustrate the present invention, numerous specific details are provided in the specific embodiments below. It should be understood by those skilled in the art that the present invention can be implemented equally without certain specific details. In other embodiments, methods, means, equipment and steps well known to those skilled in the art are not described in detail to highlight the gist of the present invention.
[0069] Unless otherwise defined, all technical and scientific terms used herein have the same meanings as those commonly understood by those skilled in the art. Unless otherwise specified, the units used in this specification are all international standard units, and the numerical values and numerical ranges appearing in the present invention should be understood to include inevitable systematic errors.
[0070] Example 1: Construction and expression of recombinant type III collagen:
[0071] 1. Construction of genetically engineered Escherichia coli
[0072] The amino acid sequence corresponding to the recombinant type III collagen constructed in this example and the nucleotide sequence encoding the amino acid sequence are shown below:
[0073] (1) Amino acid sequence of recombinant type III collagen T3A4:
[0074] ENLYFQGGKGEMGPAGIPGAPGLMGARGPPGPAGANGGKGEMGPA GIPGAPGLMGARGPPGPAGANGGKGEMGPAGIPGAPGLMGARGPPGPAG ANGGKGEMGPAGIPGAPGLMGARGPPGPAGAN (SEQ ID NO: 1)
[0075] Nucleotide sequence of recombinant type III collagen T3A4:
[0076] GAAAATCTATATTTTCAAGGTGGGAAAGGAGAGATGGGTCCGGCAGGCATCCCGGGCGCACCGGGCCTGATGGGTGCGCGTGGTCCGCCGGGTCCGGCGGGTGCCAATGGTGGCAAGGGCGAAATGGGTCCGGCAGGTATCCCGGGCGCGCCAGGCCTGATGGGTGCTCGTGGCCCACCGGGCCCGGCGGGTGCCAACGGTGGTAAAGGCGAGATGGGTCCGGCAGGCATTCCGGGCGCTCCGGGTCTGATGGGCGCGCGTGGTCCACCGGGTCCGGCCGGTGCGAACGGCGGTAAGGGTGAAATGGGTCCGGCTGGCATTCCGGGTGCGCCGGGCTTGATGGGCGCTCGCGGTCCGCCTGGTCCGGCGGGCGCGAAC(SEQ ID NO:2)
[0077] (2) Amino acid sequence of recombinant type III collagen T3A8:
[0078] ENLYFQGGKGEMGPAGIPGAPGLMGARGPPGPAGANGGKGEMGPAGIPGAPGLMGARGPPGPAGANGGKGEMGPAGIPGAPGLMGARGPPGPAGANGGKGEMGPAGIPGAPGLMGARGPPGPAGANGGKGEMGPAGIPGAPGLMGARGPPGPAGANGGKGEMGPAGIPGAPGLMGARGPPGPAGANGGKGEMGPAGIPGAPGLMGARGPPGPAGANGGKGEMGPAGIPGAPGLMGARGPPGPAGAN(SEQ ID NO:3)
[0079] Nucleotide sequence of recombinant type III collagen T3A8:
[0080] GAAAATCTATATTTTCAAGGTGGGAAAGGAGAGATGGGTCCGGCGGGCATCCCGGGCGCTCCGGGCTTGATGGGTGCCCGTGGTCCGCCGGGTCCGGCTGGCGCCAACGGTGGTAAGGGTGAAATGGGCCCGGCTGGTATCCCGGGCGCGCCGGGCCTCATGGGCGCTCGCGGCCCACCGGGCCCCGCGGGCGCGAACGGTGGCAAGGGTGAGATGGGTCCGGCTGGCATTCCGGGCGCGCCGGGCCTGATGGGTGCTCGTGGTCCACCGGGTCCGGCGGGTGCAAATGGTGGTAAGGGCGAAATGGGTCCGGCAGGCATTCCGGGTGCGCCGGGCCTGATGGGTGCGAGAGGTCCGCCGGGCCCAGCGGGTGCGAATGGTGGCAAGGGCGAGATGGGCCCGGCGGGTATTCCGGGCGCACCGGGTTTGATGGGTGCGCGTGGTCCACCGGGCCCAGCTGGCGCGAACGGCGGTAAAGGTGAGATGGGTCCGGCAGGTATTCCGGGGGCGCCTGGCCTGATGGGTGCCCGTGGTCCGCCGGGTCCGGCCGGTGCCAACGGCGGTAAAGGCGAAATGGGTCCGGCGGGCATCCCGGGTGCACCGGGTCTGATGGGCGCACGCGGTCCGCCGGGCCCGGCAGGTGCCAATGGCGGAAAAGGTGAAATGGGCCCGGCGGGCATCCCGGGTGCGCCGGGTCTGATGGGTGCGCGTGGCCCGCCTGGTCCTGCGGGTGCGAAC(SEQ ID NO:4)
[0081] (3) Amino acid sequence of recombinant type III collagen T3A16:
[0082] ENLYFQ
[0083] GGKGEMGPAGIPGAPGLMGARGPPGPAGANGGKGEMGPAGIPGAPG
[0084] LMGARGPPGPAGAN
[0085] GGKGEMGPAGIPGAPGLMGARGPPGPAGANGGKGEMGPAGIPGAPG
[0086] LMGARGPPGPAGAN
[0087] GGKGEMGPAGIPGAPGLMGARGPPGPAGANGGKGEMGPAGIPGAPG
[0088] LMGARGPPGPAGAN
[0089] GGKGEMGPAGIPGAPGLMGARGPPGPAGANGGKGEMGPAGIPGAPG
[0090] LMGARGPPGPAGAN
[0091] GGKGEMGPAGIPGAPGLMGARGPPGPAGANGGKGEMGPAGIPGAPG
[0092] LMGARGPPGPAGAN
[0093] GGKGEMGPAGIPGAPGLMGARGPPGPAGANGGKGEMGPAGIPGAPG
[0094] LMGARGPPGPAGAN
[0095] GGKGEMGPAGIPGAPGLMGARGPPGPAGANGGKGEMGPAGIPGAPG
[0096] LMGARGPPGPAGAN
[0097] GGKGEMGPAGIPGAPGLMGARGPPGPAGANGGKGEMGPAGIPGAPGLMGARGPPGPAGAN(SEQ ID NO:5)
[0098] Nucleotide sequence of recombinant type III collagen T3A16:
[0099]
[0100] CCGGGACTGATGGGTGCACGCGGTCCGCCTGGCCCAGCCGGCGC
[0101] CAACGGCGGTAAAGGTGAAATGGGTCCGGCTGGTATCCCGGGCGCACCGGGCTTGATGGGCGCGCGTGGTCCTCCGGGTCCGGCTGGCGCTAAT(SEQ ID NO:6)
[0102] (4) Amino acid sequence of recombinant type III collagen T3B4:
[0103] ENLYFQ
[0104] GERGETGPPGPAGFPGAPGQNGEPGGKGER
[0105] GERGETGPPGPAGFPGAPGQNGEPGGKGER
[0106] GERGETGPPGPAGFPGAPGQNGEPGGKGER
[0107] GERGETGPPGPAGFPGAPGQNGEPGGKGER(SEQ ID NO:7) Nucleotide sequence of recombinant type III collagen T3B4:
[0108] GAGAATCTATATTTTCAAGGAGAAAGGGGGGAAACCGGTCCGCCGGGCCCAGCGGGTTTCCCGGGTGCCCCGGGCCAGAATGGCGAGCCGGGTGGCAAGGGTGAGAGAGGCGAACGTGGTGAAACGGGTCCTCCGGGCCCGGCGGGTTTTCCGGGCGCTCCGGGCCAGAACGGCGAGCCGGGCGGTAAAGGCGAGCGTGGCGAGCGCGGTGAAACCGGTCCGCCGGGCCCAGCGGGTTTTCCGGGTGCGCCAGGCCAAAACGGTGAACCGGGTGGTAAAGGTGAGCGTGGTGAGCGCGGTGAAACCGGTCCGCCGGGTCCGGCTGGCTTCCCGGGCGCACCGGGGCAAAACGGCGAGCCGGGCGGTAAGGGCGAACGT(SEQ ID NO:8)
[0109] (5) Amino acid sequence of recombinant type III collagen T3B8:
[0110] ENLYFQ
[0111] GERGETGPPGPAGFPGAPGQNGEPGGKGER
[0112] GERGETGPPGPAGFPGAPGQNGEPGGKGER
[0113] GERGETGPPGPAGFPGAPGQNGEPGGKGER
[0114] GERGETGPPGPAGFPGAPGQNGEPGGKGER
[0115] GERGETGPPGPAGFPGAPGQNGEPGGKGER
[0116] GERGETGPPGPAGFPGAPGQNGEPGGKGER
[0117] GERGETGPPGPAGFPGAPGQNGEPGGKGER
[0118] GERGETGPPGPAGFPGAPGQNGEPGGKGER (SEQ ID NO: 9) Nucleotide sequence of recombinant type III collagen T3B8:
[0119] GAGAATCTATATTTTCAAGGAGAAAGGGGGGAGACGGGTCCGCCTGGCCCAGCGGGCTTTCCGGGTGCGCCGGGCCAGAACGGTGAGCCGGGCGGTAAGGGTGAACGTGGTGAGCGTGGCGAAACCGGTCCTCCGGGCCCGGCTGGCTTCCCGGGTGCCCCAGGTCAAAACGGTGAGCCGGGCGGTAAAGGTGAGCGTGGTGAGCGTGGTGAAACGGGCCCGCCGGGACCAGCGGGTTTCCCGGGTGCTCCGGGCCAAAACGGCGAACCGGGTGGCAAGGGTGAGCGCGGTGAACGCGGCGAAACCGGTCCGCCAGGTCCGGCAGGGTTCCCGGGTGCACCGGGTCAGAACGGCGAACCGGGCGGCAAAGGTGAGCGTGGCGAGCGTGGTGAAACCGGTCCGCCGGGTCCGGCGGGCTTTCCGGGTGCGCCAGGGCAAAATGGTGAGCCGGGCGGTAAAGGTGAGCGTGGTGAACGCGGAGAAACTGGCCCACCGGGCCCGGCGGGCTTTCCGGGCGCTCCGGGCCAGAATGGCGAGCCGGGAGGTAAGGGCGAGCGCGGGGAGCGTGGTGAAACCGGTCCGCCGGGCCCGGCGGGTTTTCCGGGCGCGCCGGGTCAGAATGGCGAACCGGGTGGCAAAGGCGAGCGCGGTGAAAGAGGCGAAACCGGCCCTCCGGGTCCGGCAGGCTTCCCGGGCGCCCCGGGTCAGAACGGTGAACCGGGTGGTAAGGGTGAGCGT(SEQ ID NO:10)
[0120] (6) Amino acid sequence of recombinant type III collagen T3B16:
[0121] ENLYFQ
[0122] GERGETGPPGPAGFPGAPGQNGEPGGKGERGERGETGPPGPAGFPGA
[0123] PGQNGEPGGKGER
[0124] GERGETGPPGPAGFPGAPGQNGEPGGKGERGERGETGPPGPAGFPGA
[0125] PGQNGEPGGKGER
[0126] GERGETGPPGPAGFPGAPGQNGEPGGKGERGERGETGPPGPAGFPGA
[0127] PGQNGEPGGKGER
[0128] GERGETGPPGPAGFPGAPGQNGEPGGKGERGERGETGPPGPAGFPGA
[0129] PGQNGEPGGKGER
[0130] GERGETGPPGPAGFPGAPGQNGEPGGKGERGERGETGPPGPAGFPGA
[0131] PGQNGEPGGKGER
[0132] GERGETGPPGPAGFPGAPGQNGEPGGKGERGERGETGPPGPAGFPGA
[0133] PGQNGEPGGKGER
[0134] GERGETGPPGPAGFPGAPGQNGEPGGKGERGERGETGPPGPAGFPGA
[0135] PGQNGEPGGKGER
[0136] GERGETGPPGPAGFPGAPGQNGEPGGKGERGERGETGPPGPAGFPGAPGQNGEPGGKGER(SEQ ID NO:11)
[0137] Nucleotide sequence of recombinant type III collagen T3B16:
[0138]
[0139] (7) Amino acid sequence of recombinant type III collagen T3C8:
[0140] ENLYFQ
[0141] GetgapglkgenglpgengapgpmgpRgapgetgapglkgenglpgengapgpmgpRgap
[0142] getgapglkgenglpgengapgpmgpRgapgetgapglkgenglpgengapgpmgpRgap
[0143] getgapglkgenglpgengapgpmgpRgapgetgapglkgenglpgengapgpmgpRgap
[0144] getgapglkgenglpgengapgpmgpRgapgetgapglkgenglpgengapgpmgpRgap (SEQ IDNO: 13)
[0145] Nucleotide sequence of recombinant type III collagen T3C8:
[0146] GAAAATCTATATTTTCAAGGAGAGACAGGGGCTCCGGGCCTGAAGGGTGAAAATGGCTTACCGGGCGAGAATGGTGCCCCCGGCCCTATGGGTCCGCGTGGCGCGCCAGGTGAAACGGGTGCGCCGGGTCTGAAAGGCGAGAACGGCCTGCCGGGTGAGAACGGCGCGCCGGGTCCGATGGGTCCGCGTGGTGCGCCAGGCGAAACCGGTGCACCGGGTCTCAAAGGTGAGAACGGCCTGCCCGGCGAAAACGGCGCACCGGGTCCGATGGGTCCGCGTGGCGCGCCGGGTGAAACCGGTGCTCCGGGCTTGAAAGGTGAGAATGGCCTGCCGGGCGAGAATGGCGCGCCGGGACCGATGGGTCCGCGCGGTGCTCCGGGCGAGACTGGTGCACCGGGCCTGAAAGGCGAGAATGGCCTGCCGGGTGAAAACGGCGCGCCGGGTCCGATGGGCCCGCGTGGTGCGCCAGGTGAAACCGGCGCCCCGGGCTTGAAGGGCGAGAACGGTCTGCCGGGTGAGAACGGTGCCCCGGGTCCGATGGGTCCGCGTGGTGCGCCGGGTGAAACCGGTGCTCCGGGTTTGAAGGGCGAAAATGGCTTGCCGGGCGAGAACGGCGCTCCGGGTCCGATGGGTCCGAGAGGCGCACCAGGTGAAACCGGTGCCCCGGGGCTTAAGGGTGAAAACGGCCTGCCGGGTGAGAACGGCGCGCCAGGTCCGATGGGCCCTCGCGGTGCGCCG(SEQ ID NO:14)
[0147] (8) Amino acid sequence of recombinant type III collagen T3D8: (SEQ ID NO: 15)
[0148] ENLYFQ
[0149] Gqpgppgppgtagfpgspgakgevgpagspgqpgppgppgtagfpgspgakgevgpagsp
[0150] gqpgppgppgtagfpgspgakgevgpagspgqpgppgppgtagfpgspgakgevgpagsp
[0151] gqpgppgppgtagfpgspgakgevgpagspgqpgppgppgtagfpgspgakgevgpagsp
[0152] gqpgppgppgtagfpgspgakgevgpagspgqpgppgppgtagfpgspgakgevgpagsp
[0153] Nucleotide sequence of recombinant type III collagen T3D8: (SEQ ID NO: 16)
[0154] GAAAATCTATATTTTCAGGGACAACCCGGGCCTCCGGGTCCACCGGGAACCGCAGGCTTTCCGGGTAGCCCGGGTGCTAAAGGTGAAGTCGGTCCGGCGGGCAGCCCGGGACAGCCGGGGCCGCCGGGCCCGCCGGGCACGGCGGGGTTTCCGGGCTCTCCGGGTGCTAAGGGTGAGGTTGGCCCGGCGGGTTCACCGGGCCAACCGGGCCCCCCGGGACCGCCCGGCACCGCTGGCTTCCCGGGTTCCCCGGGTGCGAAAGGGGAGGTAGGTCCGGCGGGCAGCCCGGGTCAACCGGGTCCGCCAGGTCCGCCAGGCACCGCGGGTTTTCCGGGCTCCCCGGGTGCCAAAGGCGAGGTGGGTCCGGCGGGTAGCCCGGGCCAACCGGGCCCACCGGGCCCGCCGGGCACGGCAGGCTTTCCGGGTAGCCCGGGTGCAAAGGGTGAAGTGGGCCCAGCCGGTAGCCCGGGCCAGCCGGGTCCACCTGGCCCGCCGGGCACCGCCGGCTTCCCGGGTTCCCCGGGTGCCAAAGGCGAAGTTGGTCCGGCTGGTTCTCCGGGTCAGCCGGGTCCGCCGGGTCCTCCGGGTACTGCGGGTTTCCCGGGTAGCCCGGGTGCGAAGGGCGAAGTTGGTCCGGCGGGTAGTCCTGGTCAGCCGGGGCCGCCTGGCCCACCAGGCACCGCGGGTTTCCCGGGCAGCCCGGGCGCTAAGGGTGAGGTGGGCCCGGCAGGCTCGCCG
[0155] (9) Amino acid sequence of recombinant type III collagen T3E8:
[0156] ENLYFQ
[0157] GqpgdkgeggapglpgiagpRgspGERgetgqpgdkgeggapglpgiagpRgspGERget
[0158] gqpgdkgeggapglpgiagpRgspGERgetgqpgdkgeggapglpgiagpRgspGERget
[0159] gqpgdkgeggapglpgiagpRgspGERgetgqpgdkgeggapglpgiagpRgspGERget
[0160] gqpgdkgeggapglpgiagpRgspGERgetgqpgdkgeggapglpgiagpRgspGERget(SEQ IDNO: 17)
[0161] Nucleotide sequence of recombinant type III collagen T3E8:
[0162] GAAAATCTATATTTTCAGGGACAACCCGGGGACAAAGGCGAGGGTGGTGCGCCAGGGTTGCCGGGCATTGCGGGTCCGCGTGGTAGCCCGGGAGAACGTGGTGAAACGGGCCAACCGGGCGACAAAGGTGAAGGCGGAGCACCGGGCCTGCCGGGCATTGCTGGCCCACGTGGTTCGCCGGGCGAACGCGGCGAAACCGGTCAACCGGGAGATAAGGGTGAGGGTGGCGCACCGGGTCTGCCTGGGATCGCGGGCCCACGTGGTAGCCCGGGCGAGCGCGGTGAGACCGGTCAGCCGGGCGATAAAGGCGAGGGCGGTGCGCCGGGCCTGCCGGGTATCGCCGGTCCGCGTGGTAGCCCGGGCGAGCGCGGAGAAACCGGCCAGCCGGGCGACAAGGGTGAAGGTGGTGCTCCGGGTCTGCCTGGCATTGCGGGTCCGAGAGGCTCTCCGGGCGAGCGTGGCGAAACCGGCCAGCCGGGTGATAAAGGCGAAGGTGGTGCACCGGGTTTACCGGGTATTGCGGGTCCGCGTGGCTCCCCGGGTGAGCGCGGTGAGACGGGTCAACCGGGTGACAAGGGTGAGGGCGGCGCTCCGGGTCTGCCGGGCATCGCCGGTCCGCGTGGTAGCCCTGGCGAGCGCGGTGAAACCGGTCAGCCGGGCGATAAGGGTGAGGGTGGTGCGCCGGGGTTGCCAGGCATCGCGGGCCCACGTGGTTCCCCGGGGGAGCGTGGTGAAACT(SEQ ID NO: 18)
[0163] (10) Amino acid sequence of recombinant type III collagen T3F8:
[0164] ENLYFQ
[0165] gqngepggkGERgapGEKgeggppgvagppggsgqngepggkGERgapGEKgeggppg
[0166] vagppggs
[0167] gqngepggkGERgapGEKgeggppgvagppggsgqngepggkGERgapGEKgeggppg
[0168] vagppggs
[0169] gqngepggkGERgapGEKgeggppgvagppggsgqngepggkGERgapGEKgeggppg
[0170] vagppggs
[0171] gqngepggkGERgapGEKgeggppgvagppggsgqngepggkGERgapGEKgeggppgvagppggs (SEQ ID NO: 19)
[0172] Nucleotide sequence of recombinant type III collagen T3F8:
[0173] GAAAATCTATATTTTCAGGGACAAAACGGGGAGCCGGGCGGGAAAGGTGAACGTGGTGCGCCGGGCGAAAAAGGTGAAGGCGGTCCGCCTGGTGTTGCCGGTCCGCCGGGCGGTAGCGGTCAAAACGGCGAACCGGGCGGTAAGGGTGAACGTGGTGCTCCGGGCGAAAAAGGCGAGGGTGGCCCGCCGGGCGTGGCAGGCCCGCCGGGTGGTTCGGGCCAGAATGGCGAACCTGGCGGTAAAGGTGAGCGCGGTGCTCCGGGTGAGAAGGGCGAGGGCGGACCGCCGGGCGTGGCGGGTCCGCCGGGTGGCTCCGGCCAAAACGGCGAACCGGGTGGTAAAGGCGAGCGTGGTGCGCCGGGTGAAAAAGGCGAGGGTGGCCCACCGGGTGTAGCGGGTCCGCCGGGTGGAAGCGGTCAGAACGGTGAACCGGGTGGTAAGGGTGAGAGAGGCGCACCGGGTGAAAAGGGCGAAGGCGGCCCACCGGGTGTTGCGGGTCCGCCTGGTGGTAGCGGTCAGAACGGCGAACCGGGTGGCAAGGGTGAGCGTGGTGCTCCGGGTGAGAAGGGTGAGGGCGGCCCGCCGGGGGTGGCCGGTCCCCCGGGGGGTAGCGGTCAGAATGGCGAGCCGGGTGGGAAAGGCGAGCGTGGTGCGCCAGGTGAAAAAGGCGAGGGCGGCCCACCGGGCGTCGCAGGCCCGCCGGGTGGCTCTGGTCAAAACGGTGAACCGGGCGGCAAGGGTGAGCGCGGTGCGCCAGGCGAGAAGGGCGAAGGTGGTCCGCCGGGTGTTGCGGGTCCGCCGGGCGGCTCC(SEQ ID NO: 20)
[0174] (11) Amino acid sequence of recombinant type III collagen T3G8:
[0175] ENLYFQ
[0176] GpRgpvgpsgppgkdgtsghpgpigppgpRgnRGERgpRgpvgpsgppgkdgtsghpgpig
[0177] ppgpRgnRGER
[0178] gpRgpvgpsgppgkdgtsghpgpigppgpRgnRGERgpRgpvgpsgppgkdgtsghpgpig
[0179] ppgpRgnRGER
[0180] gpRgpvgpsgppgkdgtsghpgpigppgpRgnRGERgpRgpvgpsgppgkdgtsghpgpig
[0181] ppgpRgnRGER
[0182] gpRgpvgpsgppgkdgtsghpgpigppgpRgnRGERgpRgpvgpsgppgkdgtsghpgpigppgpRgnRGER (SEQ ID NO: 21)
[0183] Nucleotide sequence of recombinant type III collagen T3G8:
[0184] GAAAATCTATATTTTCAAGGACCCAGGGGGCCCGTGGGTCCGAGCGGTCCGCCGGGCAAGGACGGCACCTCTGGTCACCCGGGCCCCATCGGTCCACCGGGTCCGCGTGGTAATCGCGGTGAACGCGGTCCGAGAGGCCCGGTTGGTCCTTCCGGACCTCCGGGTAAGGATGGTACTTCAGGCCATCCGGGTCCTATTGGCCCACCGGGTCCGCGTGGTAATCGTGGTGAACGTGGCCCTCGCGGTCCGGTAGGTCCGAGCGGTCCGCCAGGCAAAGATGGCACCAGCGGTCACCCGGGGCCCATCGGCCCACCGGGCCCGCGTGGCAACCGCGGCGAGCGTGGTCCGCGTGGTCCTGTTGGCCCAAGCGGTCCTCCGGGCAAAGATGGTACGTCTGGCCACCCGGGTCCGATCGGCCCACCGGGCCCGAGAGGCAATCGTGGTGAGCGCGGCCCCCGTGGTCCGGTCGGTCCGAGCGGTCCGCCGGGTAAGGACGGCACCAGCGGCCACCCTGGACCGATTGGTCCGCCGGGTCCGCGCGGAAACCGCGGTGAGCGCGGTCCGCGTGGCCCGGTGGGTCCGAGTGGCCCACCGGGCAAAGACGGCACCTCGGGTCACCCGGGTCCGATTGGTCCGCCGGGTCCGCGTGGAAACCGTGGTGAACGTGGCCCGCGTGGCCCCGTGGGTCCGAGCGGCCCACCGGGCAAAGATGGTACGTCCGGTCATCCGGGCCCGATTGGCCCGCCGGGCCCGCGTGGAAACCGTGGCGAACGCGGTCCGCGTGGTCCGGTTGGTCCGAGCGGTCCGCCGGGCAAGGACGGCACCTCCGGCCATCCGGGTCCCATCGGTCCGCCGGGTCCGAGAGGCAACCGTGGTGAGCGT(SEQ ID NO:22)
[0185] When the recombinant type III collagen of the present invention is expressed, an amino acid sequence ENLYFQ (SEQ ID NO: 23) that can be removed by TEV protease is added to its N-terminus; preferably, the amino acid sequence that can be removed by TEV protease is directly connected to the functional region sequence of the human natural type III collagen.
[0186] The nucleotide sequences of the above-mentioned recombinant type III collagen SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20 and 22 were cloned into the multiple cloning site of the expression vector to obtain the corresponding recombinant expression vector, and then the recombinant expression vector was transferred into the Escherichia coli expression strain to screen and obtain the genetically engineered Escherichia coli. The specific operation is:
[0187] i) According to the amino acid sequence of recombinant type III collagen (specifically SEQ ID NO: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19 and 21), the codon gene preferred by Escherichia coli was optimized and selected to obtain the corresponding nucleotide sequences, namely SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20 and 22.
[0188] Beijing Shengyuan Kemeng Biotechnology Co., Ltd. was commissioned to transfer the gene fragments of recombinant type III collagen T3A4, T3A8, T3A16, T3B4, T3B8, T3B16, T3C8, T3D8, T3E8, T3F8 and T3G8 through Kpn I (NEB product number: R0136L) and Xho I (NEB, catalog number: R0146L) were inserted into the pET-32a expression vector (Beijing Shengyuan Kemeng Biotechnology Co., Ltd.) to construct pET-32a-T3A4, pET-32a-T3A8, pET-32a-T3A16, pET-32a-T3B4, pET-32a-T3B8, pET-32a-T3B16, pET-32a-T3C8, pET-32a-T3D8, pET-32a-T3E8, pET-32a-T3F8 and pET-32a-T3G8 recombinant expression vectors, and the above recombinant expression vectors were introduced into Escherichia coli BL21 (DE3) (Merck) to screen positive Escherichia coli genetically engineered bacteria. The specific process is:
[0189] 1: Take 1 μl of the plasmid and put it into 100 μl of E. coli competent cells BL21 (DE3) and let it stand on ice for 30 minutes.
[0190] 2: Heat shock the mixture in a 42°C water bath for 90 seconds, then quickly place on ice for 2 minutes.
[0191] 3: Add 600 μl of LB medium without resistance to the mixture and culture at 37°C and 220 rpm for 1 h.
[0192] 4: Take 200 μl of the bacterial solution and spread it evenly on an LB plate containing ampicillin resistance (10 g / L peptone, 5 g / L yeast extract, 10 g / L sodium chloride, 15 g / L agar, 100 μg / ml ampicillin antibiotic).
[0193] 5: Invert the plate and culture it in a 37°C incubator for about 20 hours until clearly visible colonies grow.
[0194] 2. Fermentation and induced expression of genetically engineered Escherichia coli
[0195] a. Pick a single colony of the optimal genetically engineered Escherichia coli from the LB plate, add it to 5 ml of LB medium (10 g / L peptone, 5 g / L yeast extract, 10 g / L sodium chloride), and culture it in a shaking incubator at 220 rpm and 37°C overnight.
[0196] b. Inoculate the bacterial solution into LB medium at a ratio of 1:100 for amplification and culture at 220 rpm and 37°C for 7 hours. 600 When the p-value was about 0.6, IPTG was added at a final concentration of 0.5 mM for induction, the temperature was lowered to 16°C, and the induction culture was continued overnight; the proteins expressed at this time were named T3A4, T3A8, T3A16, T3B4, T3B8, T3B16, T3C8, T3D8, T3E8, T3F8, and T3G8, and the bacteria were collected by centrifugation.
[0197] c. Resuspend the collected bacteria with balanced working solution (25mM Tris, 200mM sodium chloride and 20mM imidazole), cool the bacterial solution to ≤15°C, homogenize, and homogenize twice under high pressure. Collect the bacterial solution after completion. Dispense the homogenized bacterial solution into centrifuge bottles, centrifuge at 17000rpm and 4°C for 30min, collect the supernatant, and take the supernatant and precipitate for electrophoresis detection.
[0198] 3. Purification of Recombinant Type III Collagen
[0199] a. Wash the column with water for 5 CV. b. Equilibrate the column with equilibration solution (200mM sodium chloride, 25mM Tris, 20mM imidazole) for 5 CV. c. Loading: Add the supernatant after centrifugation to the column until the liquid flows out. d. Wash the impurities: Add 25mL of washing solution (200mM sodium chloride, 25mM Tris, 20mM imidazole) until the liquid flows out. e. Collect the target protein: Add 25mL of elution solution (200mM sodium chloride, 25mM Tris, 250mM imidazole), and collect the flow-through to obtain the target polypeptides Trx-T3A4, Trx-T3A8, Trx-T3A16, Trx-T3B4, Trx-T3B8, Trx-T3B16, Trx-T3C8, Trx-T3D8, Trx-T3E8, Trx-T3F8 and Trx-T3G8. The eluted target polypeptide is detected by electrophoresis.
[0200] 4. Electrophoresis detection
[0201] The molecular weight and purity of the target polypeptides Trx-T3A4, Trx-T3A8, Trx-T3A16, Trx-T3B4, Trx-T3B8, Trx-T3B16, Trx-T3C8, Trx-T3D8, Trx-T3E8, Trx-T3F8 and Trx-T3G8 prepared in the above section "3. Purification of recombinant type III collagen" were detected by SDS-PAGE. The specific process is as follows: take 40 μl of the purified polypeptide solution, add 10 μl of 5× protein loading buffer (250 mM Tris-HCl (pH: 6.8), 10% SDS, 0.5% bromophenol blue, 50% glycerol, 5% β-mercaptoethanol), place in 100°C boiling water for 10 min, then add 10 μl to each well of SDS-PAGE protein gel, run at 80 V for 2 h, use Coomassie Brilliant Blue staining solution (0.1% Coomassie Brilliant Blue R-250, 25% isopropanol, 10% glacial acetic acid) for protein staining for 20 min, and then use protein decolorization solution (10% acetic acid, 5% ethanol) for decolorization.
[0202] Test results such as Figure 1 As shown, polypeptides Trx-T3A4, Trx-T3A8, Trx-T3A16, Trx-T3B4, Trx-T3B8, Trx-T3B16, Trx-T3C8, Trx-T3D8, Trx-T3E8, Trx-T3F8 and Trx-T3G8 were correctly expressed.
[0203] 5. Detection of protein concentration and yield
[0204] (1) Accurately measure appropriate amounts of the target polypeptides Trx-T3A4, Trx-T3A8, Trx-T3A16, Trx-T3B4, Trx-T3B8, Trx-T3B16, Trx-T3C8, Trx-T3D8, Trx-T3E8, Trx-T3F8 and Trx-T3G8 prepared in the section "3. Purification of recombinant type III collagen" above, dilute 10-50 times with eluent (200 mM sodium chloride, 25 mM Tris, 250 mM imidazole), and stir well with a glass rod. Use a UV-visible spectrophotometer to measure the absorbance at 280 nm, and calculate the protein concentration according to the formula C (mg / ml) = A280 × absorbance coefficient × dilution factor (Note: the absorbance value must be between 0.1 and 1).
[0205] The absorbance coefficients, dilution multiples and A280 values of different recombinant type III collagens are shown in Table 1 below:
[0206] Table 1 Absorption coefficient, dilution multiple and A280 value of different recombinant type III collagen
[0207]
[0208] (2) Detection of the yield of recombinant type III collagen was performed according to the following method:
[0209] Protein yield = protein expression (g) ÷ bacterial weight (g) × 100%
[0210] [Test results] The results of protein concentration and yield are shown in Table 2 below:
[0211] Table 2 Bacterial weight, concentration, protein expression and yield of different recombinant type III collagen
[0212]
[0213]
[0214] Experimental conclusion:
[0215] 1. According to the results shown in Table 2, the expression levels of different recombinant type III collagen are as follows: T3G8>T3C8>T3F8>T3B16>T3B8>T3D8>T3B4>T3A16>T3E8>T3A4>T3A8;
[0216] 2. According to Figure 1 The results shown show that: (i) there is no obvious target protein in the eluates of recombinant type III collagen T3A4 and T3A8, and no obvious target protein expression.
[0217] (ii) The protein expression level of T3B4 (theoretical molecular weight of crude purification is 28.4 kDa) is low, and the target protein is contained in the eluate; the protein expression level of T3B8 (theoretical molecular weight of crude purification is 39.6 kDa) is low, and the target protein is clearly contained in the eluate; the protein expression level of T3D8 (theoretical molecular weight of crude purification is 37.7 kDa) is low, and the target protein is clearly contained in the eluate; the protein expression level of T3F8 (theoretical molecular weight of crude purification is 40.2 kDa) is high, and the target protein is clearly contained in the eluate; the protein expression level of T3C8 (theoretical molecular weight of crude purification is 39.0 kDa) is low, and the target protein is clearly contained in the eluate. The expression level of T3E8 (theoretical molecular weight of crude purification is 39.1kDa) protein is small, and the target protein in the eluate is relatively small; the expression level of T3A16 (theoretical molecular weight of crude purification is 58.5kDa) protein is small, and the eluate contains the target protein; the expression level of T3B16 (theoretical molecular weight of crude purification is 62.0kDa) protein is small, and the eluate contains the target protein, and there are more degradation bands; the expression level of T3G8 (theoretical molecular weight of crude purification is 44.3kDa) protein is small, and the eluate contains the target protein, and there are more miscellaneous bands.
[0218] It should be noted that, although the technical solution of the present invention is introduced with specific examples, those skilled in the art will appreciate that the present invention should not be limited thereto.
[0219] The embodiments of the present invention have been described above, and the above description is exemplary, not exhaustive, and is not limited to the disclosed embodiments. Many modifications and variations will be apparent to those of ordinary skill in the art without departing from the scope and spirit of the described embodiments. The selection of terms used herein is intended to best explain the principles of the embodiments, practical applications, or technical improvements in the market, or to enable other persons of ordinary skill in the art to understand the embodiments disclosed herein.
Claims
1. A recombinant type III collagen, It is characterized in that The amino acid sequence of the recombinant type III collagen is shown as SEQ ID NO.
21.
2. The recombinant type III collagen according to claim 1, It is characterized in that The amino acid sequence of the recombinant type III collagen contains an amino acid sequence that can be removed by TEV protease, and the amino acid sequence that can be removed by TEV protease is shown in SEQ ID NO.
23. 3 . The recombinant type III collagen according to claim 2 , wherein the amino acid sequence that can be removed by TEV protease is located at the N-terminus of the recombinant type III collagen.
4. A polynucleotide encoding the recombinant type III collagen according to claim 2, the sequence of the polynucleotide being shown as SEQ ID NO.
22.
5. A recombinant expression vector, It is characterized in that The recombinant expression vector comprises the polynucleotide according to claim 4. The recombinant expression vector according to claim 5 , wherein the recombinant expression vector comprises a pET series vector, a shuttle vector or a viral vector. The recombinant expression vector according to claim 6 , wherein the recombinant expression vector is pET-32a.
8. A recombinant host cell, It is characterized in that The recombinant host cell comprises the recombinant expression vector according to any one of claims 5 to 7.
9. The recombinant host cell according to claim 8, which is a prokaryotic cell or a eukaryotic cell. 10 . The recombinant host cell according to claim 9 , which is yeast or Escherichia coli BL21 (DE3).
11. The method for preparing recombinant type III collagen according to claim 1 or 2, wherein The following steps are involved: S1: fermenting and culturing the recombinant host cell according to claim 8 to induce protein expression; S2: collecting the protein; S3: Purify the protein.
12. The preparation method according to claim 11, wherein in step S3, a Ni affinity chromatography column and / or an ion exchange chromatography column is used to purify the protein.
13. The preparation method according to claim 11, It is characterized in that In the step S1, the fermentation culture is carried out in a shaking incubator at a rotation speed of 200 to 240 rpm and a temperature of 35 to 38°C.
14. The preparation method according to claim 13, wherein the fermentation culture is carried out in a shaking incubator at a rotation speed of 220 rpm and a temperature of 37°C.
15. The preparation method according to any one of claims 11 to 14, It is characterized in that In the step S1, the specific operation of inducing protein expression is: adding IPTG to the amplified cultured bacterial solution and cooling it to 16°C. The preparation method according to claim 15 , wherein the final concentration of IPTG is 0.3-0.7 mM.
17. The preparation method according to claim 16, wherein the final concentration of IPTG is 0.5 mM.
18. The preparation method according to any one of claims 11 to 14, wherein in the step S2, the specific operation of collecting the protein is: resuspending the bacterial cells obtained in the step S1 with a balanced working solution containing 20-30 mM Tris, 150-250 mM sodium chloride and 15-25 mM imidazole, cooling the bacterial solution to 4-15°C, and centrifuging at 15000-18000 rpm for 20-40 min at 4°C after high-pressure homogenization.
19. Use of the recombinant type III collagen according to claim 1 or 2 in the preparation of a product having cell adhesion effect, wherein the product comprises a medical device, a cosmetic or a medicine.
Citation Information
Patent Citations
Pichia pastoris engineering bacteria of secretory expression human III type alpha chain collagen and construction method and application thereof
CN103725623A
Recombinant human collagen and application thereof
CN110194795A
Recombinant I-type humanized collagen C1L4T as well as preparation method and application thereof
CN113788891A
Preparation method of biosynthetic human body structural material
CN114940712A
Hydroxyproline modified recombinant III-type humanized collagen as well as preparation method and application thereof
CN115991764A
